Tennessee Retina is an active participant in many national research trials. The efforts of our physicians and patients have led to the approval of many treatments now considered to be the standard of care, and our continuing involvement in clinical research offers access to new and potentially superior treatments to patients with sight-threatening conditions.
Please call 615-983-6000 for more information and participation criteria in our active clinical trials.
Active Clinical trials
Age Related Macular Degeneration – AMDNovartis – A 16 week evaluation of an investigational handheld device to track the visual function in people who have wet AMD. Open for enrollmentGenentech/Roche Mahalo Study – A Phase Ib/II controlled study of safety, tolerability and evidence of activity of Anti-Factor D intravitreal injections administered monthly or every other month to patients with geographic atrophy (GA). Open for enrollment
HiPED Study – An Investigator Sponsored Trial (IST) evaluating High dose ranibizumab (Lucentis®) for persistent Pigment Epithelial Detachments (PED) in neovascular AMD. Open for enrollment
Genentech Harbor Study – Evaluating dosing intervals and doses (0.5mg and 2.0mg) of ranibizumab (Lucentis®) for the treatment of wet AMD.
Neovista CABERNET Study (CNV Secondary to AMD Treated with BEta RadiatioN Epiretinal Therapy) - Compares epiretinal beta radiation therapy to the standard treatment with Lucentis® injections. www.neovistainc.com
NIH CATT Study (Comparison of Age-related Macular Degeneration Treatment Trials) - Compares the safety, effectiveness and treatment intervals of Lucentis® versus Avastin injections in the treatment of wet AMD. www.med.upenn.edu/cpob/studies/CATT.shtml
DO-DO Study – An IST that compares dosing intervals using standard dose, DOuble DOse as well as quadruple dose of ranibizumab (Lucentis®) injections for the treatment of wet AMD. Open for enrollment
Regeneron View 1 Study – Compares the effectiveness of the drug VEGF-Trap eye versus the standard drug Lucentis® in the treatment of wet AMD.
Regeneron 0702 Study – An Open label safety study of intravitreal VEGF - Trap eye in patients with wet AMD.
Retinal Vein Occlusion Regeneron Copernicus Study – Evaluating the safety and effectiveness of VEGF trap eye in Central Retinal Vein Occlusion (CRVO).
Genentech/Roche Shore Study – Evaluation of dosing regimens for treatment with intravitreal ranibizumab (Lucentis®) injections in subjects with macular edema following retinal vein occlusion (RVO).
Diabetic RetinopathyGenentech Rise Study – Evaluating the safety and effectiveness of ranibizumab (Lucentis®) injections for the treatment of diabetic macular edema. Fovea Topical Drop Study – Evaluating the safety and effectiveness of topical administration of two concentrations of FOV2304 (1% and 2%) for the treatment of center involving clinically significant macular edema associated with diabetic retinopathy. Open for Enrollment
Regeneron Vista study – Evaluating 2.0mg VEGF – Trap Eye on 2 treatment intervals versus laser therapy in patients with diabetic macular edema. This is a 3 year study for Regeneron. Open for Enrollment
PAST CLINICAL TRIALS
Genentech Horizon study – An open label extension study of the safety and efficacy of intravitreal ranibizumab (Lucentis®) in the treatment of neovascular AMD and retinal vein occlusion.
Genentech BRAVO Study - Evaluated the efficacy and safety of ranibizumab (Lucentis®) versus sham in subjects with macular edema secondary to Branch Retinal Vein Occlusion (BRVO).
Genentech CRUISE Study – Evaluated the efficacy and safety of ranibizumab (Lucentis®) versus sham in subjects with macular edema secondary to Central Retinal Vein Occlusion (CRVO).
Allergan Posurdex Retinal Vein Occlusion Study – Evaluated the safety and effectiveness of a new drug delivery system and steroid for the treatment of macular edema due to branch retinal vein occlusion.
Allergan Posurdex Diabetic Macular Edema Study – Evaluated the safety and effectiveness of a new drug delivery system and steroid for the treatment of macular edema due to central retinal vein occlusion.
Sirion Fenretinide Study- A controlled dose study of orally administered Fenretinide in the treatment of geographic atrophy in subjects with dry AMD. PTAMD Study (Iridex) - A multi-center, randomized study designed to assess the effectiveness of diode laser treatment in patients with non-exudative AMD in comparison with the natural progression of the disease.
Vitrase for Vitreous Hemorrhage Study (Advanced Corneal Systems) - Investigated the safety and effectiveness of intravitreal injections of Vitrase for vitreous hemorrhage.
TTT4CNV Trial (Iridex)- A multi-center, randomized study designed to assess the effectiveness of Transpupillary Thermotherapy in patients with occult subfoveal choroidal neovascularization due to AMD.
VAM Study (CIBA vision)- A multi-center safety study of the treatment of predominantly classic subfoveal CNV secondary to AMD using photodynamic therapy with verteporfin for injection.
TSV25 Clinical Trial (Bausch & Lomb, Inc)- A multi-center, prospective study to evaluate the safety and sutureless capability of the TSV25 vitrectomy system.
Ex PS DDS in the treatment of persistent macular edema (Oculex Pharmaceuticals)- A phase 2 randomized, multi-center, controlled trial to assess the safety and effectiveness of dexamethasone posterior segment drug delivery system (DEX PS DDS) in the treatment of persistent macular edema.
ANCHOR (Genentech) - A phase III, multi-center, randomized, double-masked, active treatment-controlled study of the efficacy and safety of ranibizumab compared with verteporfin photodynamic therapy in subjects with predominantly classic subfoveal neovascular age-related macular degeneration.
MARINA (Genentech) - A phase III, multi-center, randomized, double-masked, sham injection-controlled study of the efficacy and safety of rhuFab V2 in subjects with minimally classic or occult subfoveal neovascular age-related macular degeneration.
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
Our study patients are very important to us and we provide them with exceptional care and attention. Please contact your current eyecare provider to see if you may qualify for one of our studies, or contact one of our Clinical Trial staff members listed below with any questions @ 615-983-6000
Mary Ann McCain, RN, CNOR - Clinical Research Manager
Kelly Winters, COA - Clinical Research Coordinator
Sarah Hines, COA - Clinical Research Coordinator
Pam Keesee - Clinical Research Assistant
